BACKGROUND AND AIMS: Urocortin 1 (UCN) and adrenomedullin (AM) are two recently discovered neuropeptides that, due to their distribution and binding to receptors in immune cells, have emerged as potential endogenous anti-inflammatory factors. Crohn's disease is a chronic debilitating disease characterised by a Th1 driven severe inflammation of the gastrointestinal tract. This study investigated the therapeutic effect of UCN and AM in a murine model of colitis. METHODS AND RESULTS: Treatment with UCN or AM ameliorated significantly the clinical and histopathological severity of the inflammatory colitis, abrogating body weight loss, diarrhoea, and inflammation, and increased the survival rate of colitic mice. The therapeutic effect was associated with downregulation of both inflammatory and Th1 driven autoimmune responses, including regulation of a wide spectrum of inflammatory mediators. In addition, partial involvement of interleukin 10 secreting regulatory cells in this therapeutic effect was demonstrated. Importantly, UCN or AM treatments were therapeutically effective in established colitis and avoided recurrence of the disease. CONCLUSIONS: This work identifies UCN and AM as two potent anti-inflammatory factors with the capacity to deactivate the intestinal inflammatory response and restore mucosal immune tolerance at multiple levels. Consequently, both peptides represent novel multistep therapeutic approaches for the treatment of Crohn's disease and other Th1 mediated inflammatory diseases.
BACKGROUND AND AIMS: Urocortin 1 (UCN) and adrenomedullin (AM) are two recently discovered neuropeptides that, due to their distribution and binding to receptors in immune cells, have emerged as potential endogenous anti-inflammatory factors. Crohn's disease is a chronic debilitating disease characterised by a Th1 driven severe inflammation of the gastrointestinal tract. This study investigated the therapeutic effect of UCN and AM in a murine model of colitis. METHODS AND RESULTS: Treatment with UCN or AM ameliorated significantly the clinical and histopathological severity of the inflammatory colitis, abrogating body weight loss, diarrhoea, and inflammation, and increased the survival rate of colitic mice. The therapeutic effect was associated with downregulation of both inflammatory and Th1 driven autoimmune responses, including regulation of a wide spectrum of inflammatory mediators. In addition, partial involvement of interleukin 10 secreting regulatory cells in this therapeutic effect was demonstrated. Importantly, UCN or AM treatments were therapeutically effective in established colitis and avoided recurrence of the disease. CONCLUSIONS: This work identifies UCN and AM as two potent anti-inflammatory factors with the capacity to deactivate the intestinal inflammatory response and restore mucosal immune tolerance at multiple levels. Consequently, both peptides represent novel multistep therapeutic approaches for the treatment of Crohn's disease and other Th1 mediated inflammatory diseases.
Authors: B Singh; S Read; C Asseman; V Malmström; C Mottet; L A Stephens; R Stepankova; H Tlaskalova; F Powrie Journal: Immunol Rev Date: 2001-08 Impact factor: 12.988
Authors: S Fiorucci; A Mencarelli; B Palazzetti; E Distrutti; N Vergnolle; M D Hollenberg; J L Wallace; A Morelli; G Cirino Journal: Proc Natl Acad Sci U S A Date: 2001-11-20 Impact factor: 11.205
Authors: Meghan L Marre; Courtney T Darcy; Janeth Yinh; Shizuo Akira; Satoshi Uematsu; Allen C Steere; Linden T Hu Journal: Infect Immun Date: 2010-10-04 Impact factor: 3.441
Authors: Ekaterini Chatzaki; Peter A Anton; Mulugeta Million; Maria Lambropoulou; Theodoros Constantinidis; George Kolios; Yvette Taché; Dimitri E Grigoriadis Journal: World J Gastroenterol Date: 2013-03-07 Impact factor: 5.742
Authors: Salvatore Giovanni Vitale; Antonio Simone Laganà; Agnese Maria Chiara Rapisarda; Maria Giovanna Scarale; Francesco Corrado; Pietro Cignini; Salvatore Butticè; Diego Rossetti Journal: World J Clin Cases Date: 2016-07-16 Impact factor: 1.337